Clopidogrel-induced Acute Interstitial Pneumonitis: a Case Report

doi:10.21203/rs.3.rs-313291/v1

Download PDF

Case report

Clopidogrel-induced Acute Interstitial Pneumonitis: a Case Report

https://doi.org/10.21203/rs.3.rs-313291/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background In patients with cerebral infarction resulting from intracranial arterial stenosis, combined administration of clopidogrel and aspirin may be needed for the thereafter ischemic attack. Clopidogrel has an inevitable adverse effect profile, and the most common complications are related to hemorrhagic propensity.

Case presentation A 79-year-old female patient had taken aspirin (100mg/d) for old cerebral infarction, and started taking the dual antiplatelet drug consisted of aspirin and clopidogrel (75mg/d) due to severe stenosis on both anterior cerebral arteries. Two weeks later, the patient presented dyspnea started 3 days ago, which had been worsened the last 24 h. Chest computed tomography on admission showed symmetric peribronchial ground glass opacity with reticulation in both lungs. Microorganism tests, including serology and bronchoalveolar lavage for infection, were all negative. Suspecting clopidogrel-induced acute interstitial pneumonitis, we withdrew clopidogrel and initiated steroid treatment. The patient’s clinical signs and chest radiographs improved after steroid treatment, and she was discharged on the 21st day of hospitalization.

Conclusions Clopidogrel can induce acute interstitial pneumonitis as a rare complication. The present report shows the importance of recognizing this rare adverse effect of clopidogrel in clinical practice.

Medical Genetics

Clopidogrel

Cerebral infarction

Acute interstitial pneumonitis

Drug-induced lung disease

Clopidogrel is a drug in wide use for secondary prevention of atherothrombotic complications in patients with myocardial infarction and ischemic stroke[1]. It inhibits platelet aggregation, thus increases the bleeding time and reduces blood viscosity by inhibiting adenosin diphosphate (ADP) action on platelet receptors[2]. In addition, it has an inevitable adverse effect similar to other anti-platelet agents, such as ticlopidine or aspirin. The most common adverse effect is increased risk of gastro-intestinal bleeding[3, 4]. However, clopidogrel has not been known to induce interstitial lung disease. Here, we report the rare adverse effect of clopidogrel-induced interstitial pneumonitis in a patient with cerebral infarction resulting from intracranial arterial stenosis.

A 79-year-old female patient with prior cerebral infarction on the left basal ganglia admitted for an unveiled unruptured aneurysm on the right superior cerebellar artery (SCA), which was found on magnetic resonance imaging (MRI). She had taken an aspirin (100 mg/d) and atorvastatin (40 mg/d) since the occurrence of cerebral infarction as well as amlodipine (5 mg/d) and telmisartan (40 mg/d) for hypertension and metformin (1700 mg/d) for type 2 diabetes mellitus. There was neither history of autoimmune-related disease nor abnormal allergic reactions in her past medical history. Also, she had never smoked in her life.

Cerebral angiography displayed a small SCA aneurysm that had a broad neck with a maximum diameter of 2.62 mm and a neck diameter of 2.73 mm. Besides, it revealed a considerably narrowed vasculature on both anterior cerebral arteries (ACA), which can lead to a large territory infarction. Because the unruptured SCA aneurysm was small and unlikely to rupture, it was determined to be followed with periodical brain imaging. For disclosed severe stenosis on the ACA, she started taking the dual antiplatelet drug consisted of aspirin (100 mg/d) and clopidogrel (75 mg/d).

Two weeks later, she was readmitted to the hospital due to dyspnea that started 3 days prior. She complained of anorexia, nausea, dyspnea on exertion, and chest pain. The patient did not complain of cough, sputum, rhinorrhea, or chills. At the time of admission, she was hypoxic (pulse oximetry, 91% on room air), and a chest x-ray revealed features of bilateral infiltration after comparison to a chest x-ray obtained at the previous hospitalization (Fig. 1A, 1B). The patient’s initial vital signs were as follows: blood pressure, 136/66 mmHg; pulse rate, 78 beats/min; respiratory rate, 20 breaths/min; and body temperature, 36.7°C. The initial arterial blood gas analysis revealed pH 7.422, PaCO2 38.3 mmHg, PaO2 57 mmHg, SaO2 88.1% (2 L/min of oxygen with nasal prong), and laboratory tests showed the following: hemoglobin, 11.5 g/dL; white blood cell count, 7,410 cells/µL (neutrophils, 65.1%; lymphocytes, 24.3%; monocytes, 9.0%; eosinophils, 0.9%; and basophils, 0.7%); platelet count, 327,000 cells/µL; and C-reactive protein, 1.6mg/dL. The other serum biochemistry results were within normal limits as follow: aspartate aminotransferase, 19 IU/L; alanine aminotransferase, 5 IU/L; total bilirubin, 0.7 mg/dL; alkaline phosphatase, 59 IU/L; total protein, 7.0 g/dL; albumin, 3.5 g/dL; blood urea nitrogen, 7 mg/dL; and creatinine, 0.57 mg/dL. Congestive heart failure was excluded by normal ultrasound cardiography results and a normal level of serum brain natriuretic peptide.

Empirical antibiotics (piperacillin/tazobactam 4.5g every six hours plus levofloxacin 75mg every 24 hours) were started after bacterial cultures were obtained because bacterial pneumonia could not be ruled out on the chest x-rays. Enhanced chest computed tomography (CT) revealed symmetric peribronchial ground glass opacity (GGO) with reticulation in both lungs (Fig. 1C, 1D).

On the second day of hospitalization, the patient experienced a transient fever (37.8°C). In addition, oxygen saturation could not be maintained via nasal prong 5L/min, so we supplied oxygen via high flow nasal cannula (Flow 30L/min, FiO2 35%). On hospital day 4, bronchoalveolar lavage (BAL) was performed to rule out diffuse alveolar hemorrhage and atypical pneumonia. Bacterial polymerase chain reaction (PCR), viral PCR, Cytomegalovirus PCR, Pneumocystis jirovecii PCR, fungal culture, and acid-fast bacilli smear were performed with the BAL specimens. BAL revealed a clear color fluid, and no microorganisms were detected from any of the examinations. The patient’s clinical symptoms continued to deteriorate.

One day after BAL (day 5) and after ruling out all other possible causes of her symptoms, we suspected clopidogrel-associated interstitial pneumonitis. We changed superpirin to aspirin and initiated treatment with 1mg/kg/day of intravenous methylprednisolone. The patient’s clinical signs and chest x-ray improved after withdraw of clopidogrel and addition of steroid treatment (Fig. 2A). The patient was discharged on the 21st day of hospitalization with oral prednisolone 25mg/day. The oral steroid was tapered over a period of 6 months in the outpatient setting. A follow-up chest x-ray taken 6 months after discontinuation of steroids showed no recurrence, and the patient is currently doing well in daily life (Fig. 2B).

We report a case of acute interstitial pneumonitis (AIP) that occurred after administration of clopidogrel and showed features of interstitial pneumonia on chest CT. These manifestations resolved after withdrawal of the culprit drug and treatment with prednisolone.

Clopidogrel is indicated for secondary prevention of atherothrombotic events[2]. The most common adverse effect is increased risk of bleeding. Thus, uncommon cases of clopidogrel-induced acute lung injury were associated with diffuse alveolar hemorrhage[5]. In the study of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE), fewer patients (4.5%) reported dyspnea in the clopidogrel with aspirin group than in the placebo with aspirin group[4]. Some case reports about adverse respiratory effects related to clopidogrel reported non-cardiogenic pulmonary edema[6, 7]. However, our case showed a type of AIP on chest CT.

The global incidence of drug-induced interstitial lung disease (DILD) is not clearly known, but 2.5-3% are drug induced[8, 9]. Anti-cancer drugs were the leading cause of DILD in most studies, accounting for 23–51% of cases, followed by disease-modifying anti-rheumatic drugs, antibiotics, non-steroidal anti-inflammatory agents, psychiatric medications, and anti-arrhythmic agents[10]. Although cases of DILD induced by anti-platelet agents have been rarely reported, most of them were secondary to aspirin or ticlopidine. The mechanism of DILD remains unclear, but previous reports have explained it as an allergic reaction or stimulation of neutrophil function, rather than direct toxicity from chemicals[11, 12]. Since clopidogrel structurally resembles ticlopidine, which is another thienopyridine anti-platelet drug[13], the mechanism of action of clopidogrel may be identical to that of ticlopidine. The previous cases of ticlopidine-induced lung injury showed a type of bronchiolitis obliterans organizing pneumonia (BOOP), which has aggressive symptoms and a longer recovery time[14, 15]. Our case also had the pattern of cryptogenic organizing pneumonia (COP) similar to case of ticlodipine-induced interstitial lung disease. This is consistent with that clopidogrel caused comparable finding on chest CT because its structure and mechanism of action were similar to ticlodipine.

The clinical presentation and course of AIP are similar to those of ARDS. Therefore, AIP should be distinguished from ARDS by the absence of identifiable predisposing factor and systemic involvement, such as multiorgan failure[16]. A case study reported patients with ARDS after first-dosing of clopidogrel, and rapid improvement with clearance of clopidogrel[17]. The patient was underwent a right sub-temporal craniotomy for placement of two clips to the aneurysm, leaving a 4 mm residual aneurysm, and planned medication of clopidogrel. Within hours of first-time dosing of clopidogrel, patient presented a dyspnea and syncope, and chest imaging showed severe pulmonary edema without a focal consolidation. Patient was diagnosed with ARDS, but infectious and cardiogenic causes were ruled out. Upon cessation of clopidogrel, patient’s mental status and pulmonary function improved. In our patient, it was possible to differentiate AIP from ARDS by chest imaging which revealed a type of AIP rather than pulmonary edema and exclusion of infectious causes using serology and BAL. In addition, our patient didn’t have the risk factors for ARDS, such as a history of high-risk surgery, respiratory disease or smoking.

This case report has several limitations. First, clopidogrel readministration for accurate diagnosis was not performed because of probability of reoccurrence of serious adverse reaction similar to this event. Second, we did not conduct surgical or transbronchial lung biopsy (TBLB) because of possible several complications including bleeding and deterioration of hypoxia. However, we suspected drug-induced AIP based on chest CT findings, which showed interstitial pneumonia, and lack of changes in drug history other than addition of clopidogrel. Finally, the patient clinically improved only after withdraw of clopidogrel and initiation of steroid treatment.

Identification of drug-induced lung disease is difficult because the clinical, radiological, and histological findings are nonspecific. Therefore, physicians must employ rapid decision making to recognize any possible correlation with each drug in use and development of related inflammatory lung damage. This case report suggests that patients receiving clopidogrel may develop AIP, although its occurrence is rare. This is a substantial finding considering the wide use of clopidogrel as an antithrombotic agent.

AIP acute interstitial pneumonitis

ADP adenosin diphosphate

SCA superior cerebellar artery

ACA anterior cerebral artery

MRI magnetic resonance imaging

CT computed tomography

BAL bronchoalveolar lavage

GGO ground glass opacity

PCR polymerase chain reaction

DILD drug-induced interstitial lung disease

ARDS acute respiratory distress syndrome

BOOP bronchiolitis obliterans organizing pneumonia

COP cryptogenic organizing pneumonia

Ethics approval and consent to participate

The patient's written consent has been obtained for this publication. The study was approved by the ethics committee of Kyung Hee University Hospital at Gangdong (IRB No. KHNMC 2020-07-027).

Consent for publication

The patient's written consent has been obtained for this publication.

Availability of data and materials

The data that support this case report are available from the corresponding author on reasonable request, since respecting the Ethics Committee to protect patient confdentiality.

Competing interests

The authors declare that they have no competing interests.

Funding

We received no funding for this publication

Authors' contributions

Each of the authors confirms that this manuscript has not been previously published and is not currently under consideration by any other journal. Additionally, all of the authors have approved the contents of this paper and have agreed to BMC pulmonary medicine journals submission policies. Boksoon Chang contributed to conceptualization of the manuscript. Jin An wrote the original draft and Seung Hwan Lee contributed to the review of the manuscript. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

Not applicable

Geeganage CM, Diener HC, Algra A, Chen C, Topol EJ, Dengler R et al: Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke. 2012;43:1058-1066. https://10.1161/STROKEAHA.111.637686
Kirkpatrick AC, Vincent AS, Dale GL, Prodan CI: Clopidogrel use and smoking cessation result in lower coated-platelet levels after stroke. Platelets. 2020;31:236-241. https://10.1080/09537104.2019.1609661
Nathan AS, Sen S, Yeh RW: The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. Expert Opin Drug Saf. 2017;16:561-572. https://10.1080/14740338.2017.1315101
Gent M, Beaumont D, Blanchard J, Bousser MG, Coffman J, Easton JD et al: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339. https://DOI 10.1016/s0140-6736(96)09457-3
Kim Y, Lim J, Lim J, Kim S, Jung T, Choi W: Pulmonary Alveolar Hemorrhage after Clopidogrel Use for ST Elevation Myocardial Infarction. Korean Circ J. 2013;43:497-499. https://10.4070/kcj.2013.43.7.497
Erdinler IC, Ucer E, Eksik A, Akyol A, Yazici S: Noncardiogenic pulmonary edema associated with clopidogrel: A serious but unexpected side effect of clopidogrel. Can J Cardiol. 2007;23:478-480. https://Doi 10.1016/S0828-282x(07)70788-2
Sarrot-Reynauld F, Bouillet L, Bourrain JL: Severe hypersensitivity associated with clopidogrel. Ann Intern Med. 2001;135:305-306. https://10.7326/0003-4819-135-4-200108210-00028
Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The Epidemiology of Interstitial Lung-Diseases. Am J Resp Crit Care. 1994;150:967-972. https://DOI 10.1164/ajrccm.150.4.7921471
Thomeer MJ, Costabel U, Rizzato G, Poletti V, Demedts M: Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J. 2001;18:114s-118s.
Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C et al: Drug-Induced Interstitial Lung Disease: A Systematic Review. J Clin Med. 2018;7. https://ARTN 356 10.3390/jcm7100356
Rodriguez AB, Barriga C, De la Fuente M: Effects of acetylsalicylic acid on the phagocytic function of human polymorphonuclear leukocytes in vitro. Gen Pharmacol. 1989;20:151-155. https://10.1016/0306-3623(89)90007-4
Bednar MM, Dooley RH, Tapanes R, Lublin JC, Gross CE: Ticlopidine augments luminol-dependent chemiluminescence in human neutrophils. J Biolumin Chemilumin. 1995;10:85-89. https://10.1002/bio.1170100204
Phillips EJ, Knowles SR, Shear NH: Serum sickness-like reaction associated with clopidogrel. Br J Clin Pharmacol. 2003;56:583. https://10.1046/j.0306-5251.2003.01918.x
Alonso-Martinez JL, Elejalde-Guerra JI, Larrinaga-Linero D: Bronchiolitis obliterans-organizing pneumonia caused by ticlopidine. Ann Intern Med. 1998;129:71-72. https://10.7326/0003-4819-129-1-199807010-00022
Nakamura R, Imamura T, Onitsuka H, Mishima K, Ishikawa T, Nagoshi T et al: Interstitial pneumonia induced by ticlopidine. Circ J. 2002;66:773-776. https://10.1253/circj.66.773
Bouros D, Nicholson AC, Polychronopoulos V, du Bois RM: Acute interstitial pneumonia. Eur Respir J. 2000;15:412-418. https://10.1034/j.1399-3003.2000.15b31.x
Roses SM, Christianson T, Dombrowski K: Acute Respiratory Distress Syndrome Associated With Clopidogrel in a Young Male Patient. Front Med (Lausanne). 2019;6:38. https://10.3389/fmed.2019.00038

CAREchecklist.pdf

Download PDF

Version 1

posted

You are reading this latest preprint version

Clopidogrel-induced Acute Interstitial Pneumonitis: a Case Report

Status:

Version 1

Abstract

Figures

Background

Case Presentation

Discussion And Conclusions

Abbreviations

Declarations

References

Supplementary Files

Status:

Version 1